Removing the Immunotherapy Blindfold – UConn Today
|
Removing the Immunotherapy Blindfold
UConn Today “While immunotherapy holds incredible promise, it’s currently like going into battle with high tech weapons wearing a blindfold,” explains Qendro. “In patients who respond well, the outcomes are really significant, but without the personalized … |
Xconomy |
Notes From the JPM ’18 Vortex: Gene Therapy’s Reckoning and Lonely Cabs
Xconomy The annual J.P. Morgan Healthcare conference in San Francisco winds down today, meaning the remaining stragglers are either presenting to half-empty rooms or headed back to colder climes. Compared to a 2017 full of scientific milestones—FDA approvals … |
Medscape |
Few Patients Get CAR T Cells Because of ‘Insurance Snags’
Medscape Although clinical responses have been remarkable and the approval by the US Food and Drug Administration (FDA) of these novel therapies was heralded as the biggest medical news of last year, it appears that chimeric antigen receptor (CAR) T-cell … |
|
Few Patients Get CAR T Cells Because of ‘Insurance Snags’
Medscape Although clinical responses have been remarkable and the approval by the US Food and Drug Administration (FDA) of these novel therapies was heralded as the biggest medical news of last year, it appears that chimeric antigen receptor (CAR) T-cell … |
|
Few Patients Get CAR T Cells Because of ‘Insurance Snags’
Medscape Although clinical responses have been remarkable and the approval by the US Food and Drug Administration (FDA) of these novel therapies was heralded as the biggest medical news of last year, it appears that chimeric antigen receptor (CAR) T-cell … |
WBUR |
New Cancer Treatments Top $500000, Raise Daunting Questions About How To Pay
WBUR It’s one of the most effective cancer treatments so far. And one of the most expensive cancer drugs ever. That’s why cancer specialists are both excited about so-called CAR–T cell therapy — and worried about what it portends for the affordability of … |
Independent |
CRISPR-Cas: Genetic engineering’s Holy Grail
Independent COMMENT | TECHNOLOGY | Antoine Danchin | Since its introduction four decades ago, genetic engineering has been a source of high hopes for health, agriculture, and industry. But it has also provoked deep anxiety, not least owing to the laborious nature … |